摘要
背景:称为炎症细胞的细胞内多蛋白复合物作为促炎细胞因子产生的平台如IL-1β和IL-18起作用。然而,在某些条件下,炎性体会产生非典型作用,如诱导细胞死亡,焦糖症和细胞代谢改变。 目的:在哺乳动物细胞中,确定了几种类型的炎症细胞,但研究最广泛的是含有锥体结构域3(NLRP3)的NOD样受体的炎症小体,近来被报道为慢性退行性疾病的中心致病机制。许多活化剂或危险因素通过激活NLRP3炎性体发挥作用,以产生不同细胞中的各种功能变化,包括炎症,代谢或存活反应。显示了几种分子信号通路介导NLRP3炎性体的激活,并且它们与K +外排的修饰,增加的溶酶体渗漏和组织蛋白酶B的激活或增强的活性氧(ROS)产生有关。在肾脏中,认为炎症介导或促进导致终末期肾病(ESRD)的肾小球硬化病变的进展。 NLRP3炎症细胞活化可能导致肾小球炎症和其他细胞损伤,导致肾小球损伤和ESRD的发作。这种炎性细胞活化不仅发生在免疫细胞中,而且发生在住院细胞如肾小球中的内皮细胞和足细胞中。 总结:本综述简要总结了目前NLRP3炎症活化的证据和肾小球中相关分子机制,突出说明这种炎症性激活的可能的典型和非规范效应及其对不同肾小球疾病发展的潜在影响。
关键词: 炎症,肾小球硬化,炎性体,同型半胱氨酸,糖尿病
图形摘要
Current Drug Targets
Title:Inflammasome Activation in Chronic Glomerular Diseases
Volume: 18 Issue: 9
关键词: 炎症,肾小球硬化,炎性体,同型半胱氨酸,糖尿病
摘要: Background: The intracellular multiprotein complex termed the inflammasome functions as a platform of pro-inflammatory cytokine production such as IL-1β and IL-18. Under certain conditions, however, the inflammasome produces non-canonical effects such as induction of cell death, pyroptosis and cell metabolism alterations.
Objective: In mammalian cells, several types of inflammasomes were identified, but the most widely studied one is the inflammasome containing NOD-like receptor with pyrin domain 3 (NLRP3), which has recently been reported as a central pathogenic mechanism of chronic degenerative diseases. Many activators or risk factors exert their actions through the activation of the NLRP3 inflammasome to produce a variety of functional changes in different cells including inflammatory, metabolic or survival responses. Several molecular signaling pathways are shown to mediate the activation of the NLRP3 inflammasome, and they are related to the modifications in K+ efflux, increased lysosome leakage and activation of cathepsin B or enhanced reactive oxygen species (ROS) production. In the kidney, inflammation is believed to mediate or promote the progression of glomerular sclerotic pathologies resulting in end-stage renal disease (ESRD). NLRP3 inflammasome activation may turn on glomerular inflammation and other cell damages, contributing to the onset of glomerular injury and ESRD. This inflammasome activation not only occurs in immune cells, but also in residential cells such as endothelial cells and podocytes in the glomeruli. Summary: This review briefly summarizes current evidence of NLRP3 inflammasome activation and related molecular mechanisms in renal glomeruli. The possible canonical and non-canonical effects of this inflammasome activation and its potential implication in the development of different glomerular diseases are highlighted.Export Options
About this article
Cite this article as:
Inflammasome Activation in Chronic Glomerular Diseases, Current Drug Targets 2017; 18 (9) . https://dx.doi.org/10.2174/1389450117666160817103435
DOI https://dx.doi.org/10.2174/1389450117666160817103435 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Guiding Lineage Specific Differentiation of SHED for Target Tissue/Organ Regeneration
Current Stem Cell Research & Therapy In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Adult Stem Cells and Extracellular Vesicles in Acute and Chronic Kidney Injury
Current Regenerative Medicine (Discontinued) Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Vascular Endothelial Dysfunction and Nutritional Compounds in Early Type 1 Diabetes
Current Diabetes Reviews Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Current Medicinal Chemistry Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives
Current Diabetes Reviews Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets